Author: Snowfish

Why the Pfizer COVID Pill Will Break the Pandemic
May 13, 2021 Blog Post Snowfish

The Pfizer COVID pill is the latest feat of strength from the New York-based pharmaceutical firm. To pair with its robust vaccine, Pfizer recently announced the development of an experimental antiviral drug that, for all intents and purposes, will break the pandemic. Unfortunately, in a pandemic, a vaccine on its own has never been enough.

What is Stakeholder Analysis in Life Science? Why should you do it?
April 13, 2021 Blog Post Snowfish

“Stakeholder Analysis and Engagement are critical to the launch and staying power of your product.” You have heard that wisdom before, but on top of seven to nine phone calls a day and hours spent in meetings, you may not have time to complete a truly thorough Stakeholder Analysis. Still, you are bombarded with calls

Three Product Development Secrets: Learnings from Pfizer, Moderna, and J&J
April 6, 2021 Blog Post Snowfish

In possibly the greatest product development race of this century, Pfizer, Moderna, and Johnson and Johnson (J&J) have emerged victorious. These firms beat out 6 other pharmaceutical companies, including titans AstraZeneca PLC and GlaxoSmithKline, in the race to develop a COVID-19 vaccine. A lot of lessons should be learned from this pandemic. For this post,

Antibody Ambivalence: Why the Constraints on Monoclonal Antibodies in COVID-19
February 10, 2021 Blog Post Snowfish

Despite an average vaccination rate of 1.41 million doses per day in the U.S, the pandemic continues to take its toll on the population. In our last post, my colleague wrote of his relative who unfortunately contracted coronavirus. However, we are pleased to inform that she received a monoclonal antibodies treatment, and is currently recovering.

COVID-19 Monoclonal Antibodies: Missing the Critical Window is Killing People
January 22, 2021 Blog Post Snowfish

This past week, a dear family member, an older adult, found that she has COVID-19. After her husband was diagnosed and hospitalized, she got tested and was shocked to find herself positive. She immediately called her primary care physician he did not send her immediately for any treatment such as a monoclonal antibody. In fact,

COVID-19 Vaccine: Engagement of Stakeholders
January 14, 2021 Blog Post Snowfish

The year is 2021 and it is late spring. With COVID-19 vaccine quantities bountiful, you return to your preferred clinic after a year-long absence to receive the first of your two injections. In the small sterile office, it feels like you and your health care provider are the only ones in the room, a simple

Amarin Decision Update: To Europe and Beyond
December 10, 2020 Blog Post Snowfish

As the world waits for COVID-19 vaccines to become widely available, Amarin experiences a different form of anticipation, one which will see the fate of its own profitability. Our previous blog post on Amarin highlighted the disastrous effects of a U.S Court of Appeals decision to invalidate Amarin’s six patents. To briefly recap, while the

Advanced Practice Providers: A Forgotten Market Segment
November 5, 2020 Blog Post Snowfish

Image from the StarTribune. After heading into a clinic and filling out the required forms, the assistant calls you back. “Wait in room number two,” the assistant says. Once there, a medical assistant enters and takes your vitals, leaving you with the confidence a qualified person will see you soon. A short while later,

The Rush for a COVID-19 Vaccine – The Ramifications
October 8, 2020 Blog Post Snowfish

Image from Newsday. With everyone is rushing to return pre-pandemic society, it is becoming clear that a vaccine is the only way to truly get there. Anxiously, the world waits on a vaccine for COVID-19 to get us back to work, back to school, back to play, and back to basic human connection. In

Update: Pharmaceutical Mergers and Acquisitions: Will They Drive Growth?
September 17, 2020 Blog Post Snowfish

Mergers and acquisitions are a hot topic in the biopharmaceutical industry. With 2019 setting records in terms of deal value and volume for biopharmaceutical M&A, many question the purpose of these processes. In addition to increasing shareholder value, management pursues mergers and acquisitions for a variety of reasons including innovation, synergy, and portfolio realignment. In